观察硝苯地平缓释片联合厄贝沙坦片治疗高血压合并糖尿病的疗效

Therapeutic efficacy of nifedipine sustained-release tablets and irbesartan tablets in treatment of hypertension combined with diabetes mellitus

目的探讨硝苯地平缓释片(圣通平)与厄贝沙坦片联合治疗对原发性高血压(以下简称高血压)合并2型糖尿病(以下简称糖尿病)患者的应用效果。方法回顾性分析2017年10月至2018年9月在某社区服务中心治疗的112例高血压合并糖尿病患者的临床资料,依据用药方案的不同,分为观察组(硝苯地平缓释片+厄贝沙坦片,56例)与对照组(硝苯地平缓释片,56例),比较2组降压效果与肾功能指标[尿素氮(Blood urea nitrogen,BUN)、尿白蛋白排泄率(Urinary albumin excretion ratio,UAER)、尿微量白蛋白(Microalbuminuria,mAlb)]。结果治疗前,两组血压、BUN、UAER及mAlb水平对比,差异无统计学意义(P>0.05);治疗3个月后,观察组血压、UAER与mAlb水平均明显低于对照组,差异有统计学意义(P<0.05)。结论高血压合并糖尿病患者采用硝苯地平缓释片与厄贝沙坦片联合治疗后,可有效控制血压水平,利于减轻肾功能损伤。

Objective To investigate the effect of nifedipine sustained-release tablets and irbesartan tablets on patients with essential hypertension and type 2 diabetes mellitus(T2 DM).Methods The clinical data of 112 patients with hypertension and T2 DM treated in a community service center from October 2017 to September 2018 were retrospectively analyzed.According to the different drug regimen,they were divided into a trial group(nifedipine sustained-release tablets and irbesartan,56 cases)and a control group(nifedipine sustained-release tablets,56 cases).The blood pressure and renal function indexes[blood urea nitrogen(BUN)],urinary albumin excretion ratio(UAER),microalbuminuria(mAlb)]were observed and compared between two groups.Results Before the treatment,there were no significant differences in blood pressure,and BUN,UAER and mAlb levels between two groups(P>0.05).After 3 months of the treatment,the blood pressure,and UAER and mAlb levels in the trial group were significantly lower than those in the control group(P<0.05).Conclusion The combined therapy of nifedipine and irbesartan in patients with hypertension and T2 DM can effectively control the blood pressure and reduce the damage of renal function.